Surrozen, Inc (SRZN): Price and Financial Metrics
SRZN Price/Volume Stats
| Current price | $9.50 | 52-week high | $16.19 |
| Prev. close | $9.29 | 52-week low | $4.50 |
| Day low | $8.93 | Volume | 4,535 |
| Day high | $9.50 | Avg. volume | 16,571 |
| 50-day MA | $11.90 | Dividend yield | N/A |
| 200-day MA | $9.25 | Market Cap | 30.39M |
SRZN Stock Price Chart Interactive Chart >
Surrozen, Inc (SRZN) Company Bio
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
Latest SRZN News From Around the Web
Below are the latest news stories about SURROZEN INC that investors may wish to consider to help them evaluate SRZN as an investment opportunity.
SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023SRZN stock results show that Surrozen beat analyst estimates for earnings per share the second quarter of 2023. |
SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023SRZN stock results show that Surrozen missed analyst estimates for earnings per share the first quarter of 2023. |
SRZN Stock Earnings: Surrozen Misses EPS for Q3 2023SRZN stock results show that Surrozen missed analyst estimates for earnings per share the third quarter of 2023. |
Surrozen Provides Third Quarter 2023 Financial ResultsExpect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043 in severe alcoholic hepatitis and SZN-1326 in moderate to severe ulcerative colitis Strengthened portfolio through two granted patents from the USPTO related to key discoveries involving the WNT pathway and its modulatio |
Surrozen Provides Second Quarter 2023 Financial ResultsSZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company |
SRZN Price Returns
| 1-mo | N/A |
| 3-mo | 20.25% |
| 6-mo | 45.53% |
| 1-year | 2.12% |
| 3-year | -93.57% |
| 5-year | N/A |
| YTD | 1.06% |
| 2023 | 7.69% |
| 2022 | -90.96% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...